Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Viking Therapeutics, Inc.VKTX · Entity 4067 | VP, Finance and Administration | January 19, 2021 | January 19, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Viking Therapeutics, Inc.
Report date January 19, 2021 · Filed January 19, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.00001 per shareSEC Table I · non-derivative | Direct | 116,062 |
Reported balance
After 2021-01-19 transaction · row 1
1 source rowRow 1 · 2021-01-19 · Tax withholding · Disposed 1,685 · Balance 116,062 F1: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 19, 2021 Filed Jan 19, 2021 18:21 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 1,685 | $6.68 | $11,255.80 |
DisclosureSEC source: 0001209191-21-004095 · doc4.xml · nonDerivative · entry 1 MORNEAU MICHAEL · CIK 0001517780 · VP, Finance and Administration 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,062 F1 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 16:37 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 33,000 | $0.00 Strike: $5.80 | $0.00 |
DisclosureSEC source: 0001209191-21-002114 · doc4.xml · derivative · entry 4 MORNEAU MICHAEL · CIK 0001517780 · VP, Finance and Administration 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 33,000 shares Expires 2031-01-04 F5 · derivative.exercise_date: 25% of the shares subject to the option will vest on each anniversary of the grant date. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 16:37 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 2,739 | $5.80 | $15,886.20 |
DisclosureSEC source: 0001209191-21-002114 · doc4.xml · nonDerivative · entry 3 MORNEAU MICHAEL · CIK 0001517780 · VP, Finance and Administration 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,747 F4 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to performance restricted stock unit award. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 16:37 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 6,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002114 · doc4.xml · nonDerivative · entry 2 MORNEAU MICHAEL · CIK 0001517780 · VP, Finance and Administration 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,486 F3 · shares: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2019, 33.33% of which vested on January 4, 2021 upon the achievement of a non-financial performance goal. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 16:37 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 14,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002114 · doc4.xml · nonDerivative · entry 1 MORNEAU MICHAEL · CIK 0001517780 · VP, Finance and Administration 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,819 F1 · shares: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2014 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award. F2 · balance_after: Includes 1,279 shares acquired on November 20, 2020 pursuant to the Issuer's 2014 Employee Stock Purchase Plan. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 17:21 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock | 1,557 | $6.25 | $9,731.25 |
DisclosureSEC source: 0001209191-20-050734 · doc4.xml · nonDerivative · entry 2 MORNEAU MICHAEL · CIK 0001517780 · VP, Finance and Administration 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,873 F3 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to a performance restricted stock unit award. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 17:21 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-050734 · doc4.xml · nonDerivative · entry 1 MORNEAU MICHAEL · CIK 0001517780 · VP, Finance and Administration 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,430 F1 · shares: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2020, 33.33% of which vested on September 15, 2020 upon the achievement of a non-financial performance goal. F2 · balance_after: Includes 2,090 shares acquired on May 20, 2020 pursuant to the Issuer's 2014 Employee Stock Purchase Plan. Read SEC document |
| March 31, 2020 Filed Apr 3, 2020 17:47 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $4.68 | $0.00 |
DisclosureSEC source: 0001209191-20-023378 · doc4.xml · derivative · entry 1 MORNEAU MICHAEL · CIK 0001517780 · VP, Finance and Administration 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-03-31 F1 · derivative.exercise_date: 25% of the shares subject to the option will vest on each anniversary of the grant date. Read SEC document |
| January 19, 2020 Filed Jan 21, 2020 17:35 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 2,044 | $7.18 | $14,675.92 |
DisclosureSEC source: 0001209191-20-004311 · doc4.xml · nonDerivative · entry 1 MORNEAU MICHAEL · CIK 0001517780 · VP, Finance and Administration 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,840 F1 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units. F2 · balance_after: Includes 2,893 shares acquired on May 20, 2019 and November 20, 2019 pursuant to the Issuer's 2014 Employee Stock Purchase Plan. Read SEC document |
| January 03, 2020 Filed Jan 3, 2020 20:03 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0001209191-20-001428 · doc4.xml · derivative · entry 1 MORNEAU MICHAEL · CIK 0001517780 · VP, Finance and Administration 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-01-03 F1 · derivative.exercise_date: 25% of the shares subject to the option will vest on each anniversary of the grant date. Read SEC document |
| October 31, 2019 Filed Oct 31, 2019 18:27 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $6.47 | $0.00 |
DisclosureSEC source: 0001209191-19-054654 · doc4.xml · derivative · entry 1 MORNEAU MICHAEL · CIK 0001517780 · VP, Finance and Administration 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2029-10-31 F1 · derivative.exercise_date: 25% of the shares subject to the option will vest on each anniversary of the grant date. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 17:59 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $7.69 | $0.00 |
DisclosureSEC source: 0001209191-19-044336 · doc4.xml · derivative · entry 1 MORNEAU MICHAEL · CIK 0001517780 · VP, Finance and Administration 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-07-31 F1 · derivative.exercise_date: 1/3 of the shares subject to the option will vest on each anniversary of the grant date. Read SEC document |
| January 19, 2019 Filed Jan 22, 2019 19:13 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 2,044 | $8.78 | $17,946.32 |
DisclosureSEC source: 0001209191-19-004861 · doc4.xml · nonDerivative · entry 1 MORNEAU MICHAEL · CIK 0001517780 · VP, Finance and Administration 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,991 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units. Read SEC document |
| January 03, 2019 Filed Jan 3, 2019 20:35 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 29,000 | $0.00 Strike: $7.58 | $0.00 |
DisclosureSEC source: 0001209191-19-001575 · doc4.xml · derivative · entry 1 MORNEAU MICHAEL · CIK 0001517780 · VP, Finance and Administration 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,000 Underlying: Common Stock · 29,000 shares Expires 2029-01-03 F1 · derivative.exercise_date: 25% of the shares subject to the option will vest on each anniversary of the grant date. Read SEC document |
| May 31, 2018 Filed May 31, 2018 19:03 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 21,551 | $9.25 | $199,346.75 |
DisclosureSEC source: 0001209191-18-034494 · doc4.xml · nonDerivative · entry 1 MORNEAU MICHAEL · CIK 0001517780 · VP, Finance and Administration 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,035 F1 · shares: All 21,551 of the shares were acquired on May 18, 2018 pursuant to the Issuer's 2014 Employee Stock Purchase Plan. Read SEC document |
| May 04, 2018 Filed May 8, 2018 20:37 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 7,616 | $4.22 | $32,139.52 |
DisclosureSEC source: 0001209191-18-028718 · doc4.xml · nonDerivative · entry 1 MORNEAU MICHAEL · CIK 0001517780 · VP, Finance and Administration 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,035 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock. Read SEC document |
| January 19, 2018 Filed Jan 23, 2018 17:42 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 52,500 | $0.00 Strike: $4.65 | $0.00 |
DisclosureSEC source: 0001209191-18-004973 · doc4.xml · derivative · entry 2 MORNEAU MICHAEL · CIK 0001517780 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 52,500 shares Expires 2028-01-19 F3 · derivative.exercise_date: 25% of the shares subject to the option will vest on each anniversary of the grant date. Read SEC document |
| January 19, 2018 Filed Jan 23, 2018 17:42 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-004973 · doc4.xml · nonDerivative · entry 1 MORNEAU MICHAEL · CIK 0001517780 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,651 F1 · shares: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2014 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award. F2 · balance_after: Includes 3,004 shares acquired on May 19, 2017 pursuant to the Issuer's 2014 Employee Stock Purchase Plan and 3,043 shares acquired on November 20, 2017 pursuant to the Issuer's 2014 Employee Stock Purchase Plan. Read SEC document |
| May 04, 2017 Filed May 5, 2017 18:25 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 8,192 | $1.34 | $10,977.28 |
DisclosureSEC source: 0001209191-17-030443 · doc4.xml · nonDerivative · entry 1 MORNEAU MICHAEL · CIK 0001517780 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,604 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock. F2 · balance_after: Includes 147 shares acquired on May 20, 2015 pursuant to the Issuer's 2014 Employee Stock Purchase Plan, 2,643 shares acquired on November 20, 2015 pursuant to the Issuer's 2014 Employee Stock Purchase Plan, 5,694 shares acquired on May 20, 2016 pursuant to the Issuer's 2014 Employee Stock Purchase Plan, and 2,908 shares acquired on November 18, 2016 pursuant to the Issuer's 2014 Employee Stock Purchase Plan. Read SEC document |
| January 05, 2017 Filed Jan 5, 2017 19:20 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 17,605 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001209191-17-002391 · doc4.xml · derivative · entry 2 MORNEAU MICHAEL · CIK 0001517780 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,605 Underlying: Common Stock · 17,605 shares Expires 2027-01-05 F2 · shares: The Reporting Person's employment agreement with the Issuer entitles him to an annual cash bonus. The Reporting Person voluntarily elected to be paid 20% of his 2016 annual cash bonus in the form of an option to purchase shares of common stock of the Issuer. Read SEC document |
| January 05, 2017 Filed Jan 5, 2017 19:20 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 95,000 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001209191-17-002391 · doc4.xml · derivative · entry 1 MORNEAU MICHAEL · CIK 0001517780 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2027-01-05 F1 · derivative.exercise_date: 25% of the shares subject to the option will vest on each anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.